We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+56.06%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$630M
AUM Growth
+$61.5M
Cap. Flow
-$103M
Cap. Flow %
-16.29%
Top 10 Hldgs %
88.37%
Holding
28
New
1
Increased
5
Reduced
1
Closed
12

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$28.1M
2
NUVL
Nuvalent
NUVL
+$19.8M
3
ATXS
Astria Therapeutics
ATXS
+$10.2M
4
AXSM icon
Axsome Therapeutics
AXSM
+$6.87M
5
VRNA
Verona Pharma
VRNA
+$2.62M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$31M
2
INSM icon
Insmed
INSM
+$28.8M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$24.3M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$21.9M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$12.3B
$155M 24.61%
2,011,647
+115,000
+6% +$6.87M
NUVL
2
DELISTED
Nuvalent
NUVL
$83.1M 13.18%
2,788,981
+709,118
+34% +$19.8M
VRNA
3
DELISTED
Verona Pharma
VRNA
$75.1M 11.92%
2,875,526
+196,544
+7% +$2.62M
ONC
4
BeOne Medicines Ltd
ONC
$34B
$52.7M 8.35%
239,443
+153,043
+177% +$28.1M
VRDN icon
5
Viridian Therapeutics
VRDN
$2.2B
$40M 6.35%
1,369,623
– –
NBIX icon
6
Neurocrine Biosciences
NBIX
$17.8B
$33.8M 5.36%
283,000
– –
COGT icon
7
Cogent Biosciences
COGT
$6.9B
$31.9M 5.06%
2,758,975
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.49B
$29.2M 4.63%
2,543,107
– –
ATXS
9
DELISTED
Astria Therapeutics
ATXS
$28.3M 4.49%
1,901,397
+989,661
+109% +$10.2M
ARGX icon
10
argenx
ARGX
$56.1B
$27.9M 4.42%
73,526
– –
TERN
11
DELISTED
Terns Pharmaceuticals
TERN
$20.8M 3.29%
2,040,000
-10,000
-0.5% -$66.6K
ANNX icon
12
Annexon
ANNX
$875M
$17.4M 2.75%
3,358,563
– –
TRVI icon
13
Trevi Therapeutics
TRVI
$2.57B
$11M 1.74%
5,696,515
– –
DBVT
14
DBV Technologies
DBVT
$813M
$10.8M 1.71%
706,496
– –
TYRA icon
15
Tyra Biosciences
TYRA
$1.89B
$10.8M 1.71%
1,416,998
– –
ELVN icon
16
Enliven Therapeutics
ELVN
$3.8B
$2.58M 0.41%
+157,833
New +$2.52M
ACAD icon
17
Acadia Pharmaceuticals
ACAD
$4.4B
– –
-751,804
Closed -$12.3M
ALLK
18
DELISTED
Allakos
ALLK
– –
-147,189
Closed -$901K
AMRN
19
Amarin Corp
AMRN
$286M
– –
-279,242
Closed -$6.09M
AXSM icon
20
CALL
Axsome Therapeutics
AXSM
$12.3B
– –
-600,000
Closed -$26.8M
ENTA icon
21
Enanta Pharmaceuticals
ENTA
$375M
– –
-469,264
Closed -$24.3M
INSM icon
22
Insmed
INSM
$22.9B
– –
-1,336,368
Closed -$28.8M
IOVA icon
23
Iovance Biotherapeutics
IOVA
$2.2B
– –
-389,588
Closed -$3.73M
KROS icon
24
Keros Therapeutics
KROS
$205M
– –
-272,498
Closed -$10.3M
OLMA icon
25
Olema Pharmaceuticals
OLMA
$1.08B
– –
-1,231,566
Closed -$3.4M
1
2

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q4 2022 Portfolio in Review

As of Q4 2022, Fairmount Funds Management held 28 positions worth $630M, up 11% from $569M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Fairmount Funds Management withdrew a net $103M in Q4 2022, closing 12 positions and reducing 1 holding. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $31M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

Against the trend, Fairmount Funds Management opened a new position in Enliven Therapeutics worth $2.58M.

  • Fairmount Funds Management's largest Q4 2022 buy was Enliven Therapeutics: 157,833 shares worth $2.58M.
  • Fairmount Funds Management added most to BeOne Medicines Ltd in Q4 2022, an estimated $28.1M increase.
  • Fairmount Funds Management's biggest Q4 2022 reduction was Terns Pharmaceuticals, cutting an estimated $66.6K.
  • Fairmount Funds Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $31M.
  • Fairmount Funds Management's ten largest holdings make up 88% of its $630M portfolio in Q4 2022.
  • Fairmount Funds Management opened 1 new position and closed 12 in Q4 2022.
  • Fairmount Funds Management's portfolio value rose 11% quarter-over-quarter to $630M.

Based on Fairmount Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.